{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:15:47Z","timestamp":1782792947280,"version":"3.54.5"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012247","name":"Program of Shanghai Academic Research Leader","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012247","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Therapeutic agents for refractory prolactinomas that are resistant to dopamine agonists (DAs) are troublesome, and surgery often only removes a large part of the tumor without complete remission. Among the various second-line treatment regimens, the treatment effect of the alkylating agent temozolomide (TMZ) is only effective for approximately half of patients; however, complete remission is rare. Here we report a patient with prolactinoma who was resistant to high-dose cabergoline (CAB) treatment, demonstrating a continuous increase in both the tumor volume and the prolactin (PRL) level. Given that this case is a refractory prolactinoma, the patient underwent two transsphenoidal approach (TSA) surgeries. The pathological analysis indicated that the Ki-67 index increased significantly from 3% to 30%, and the expression levels of DRD2 and MGMT were low. Finally, TMZ treatment was recommended. A total of six cycles of TMZ standard chemotherapy shrank the tumor volume and the tumor disappeared completely. During the 6-month follow-up period, the tumor did not relapse again, and the PRL level was also normal. RNA sequencing and DNA whole genome sequencing were performed on this prolactinoma specimen, revealing 16 possible gene mutations, including a missense mutation of the PABPC1 gene. Additionally, the copy number variation analysis results showed that several chromosomes had copy number gains compared to the matched peripheral blood sample. In this case, low expression of DRD2 and high proliferation led to resistance to CAB, whereas low MGMT expression contributed to sensitivity to TMZ treatment. The results of genome sequencing still need further investigation at the molecular level to explain the tumor aggressiveness and high sensitivity to TMZ.<\/jats:p>","DOI":"10.3389\/fendo.2021.616339","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T14:43:16Z","timestamp":1615560196000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists"],"prefix":"10.3389","volume":"12","author":[{"given":"Hao","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe Bao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1986.65.6.0733","article-title":"Pathology of invasive pituitary tumors with special reference to functional classification","volume":"65","author":"Scheithauer","year":"1986","journal-title":"J Neurosurg"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00007","article-title":"Molecular Network Basis of Invasive Pituitary Adenoma: A Review","volume":"10","author":"Yang","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3171\/2010.11.JNS101369","article-title":"Dopamine agonist-resistant prolactinomas","volume":"114","author":"Oh","year":"2011","journal-title":"J Neurosurg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1159\/000504000","article-title":"Treatment of Pituitary and Other Tumours with Cabergoline: New Mechanisms and Potential Broader Applications","volume":"110","author":"Lin","year":"2020","journal-title":"Neuroendocrinology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02180-4","article-title":"The KBTBD6\/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment","volume":"140","author":"Liu","year":"2020","journal-title":"Acta Neuropathol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/biomedicines7030069","article-title":"Temozolomide and Other Alkylating Agents in Glioblastoma Therapy","volume":"7","author":"Strobel","year":"2019","journal-title":"Biomedicines"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00318","article-title":"Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions","volume":"9","author":"Syro","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-016-0745-y","article-title":"How effective is temozolomide for treating pituitary tumours and when should it be used","volume":"20","author":"Halevy","year":"2017","journal-title":"Pituitary"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-019-01000-7","article-title":"Aggressive prolactinomas: how to manage","volume":"23","author":"Lasolle","year":"2020","journal-title":"Pituitary"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.14310\/horm.2002.1729","article-title":"Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review","volume":"16","author":"Almalki","year":"2017","journal-title":"Hormones (Athens)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1101\/gr.107524.110","article-title":"The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1101\/gr.129684.111","article-title":"VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing","volume":"22","author":"Koboldt","year":"2012","journal-title":"Genome Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.4197","article-title":"Salmon provides fast and bias-aware quantification of transcript expression","volume":"14","author":"Patro","year":"2017","journal-title":"Nat Methods"},{"key":"B15","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1159\/000156116","article-title":"Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists","volume":"89","author":"Passos","year":"2009","journal-title":"Neuroendocrinology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018097","article-title":"Dopamine- induced apoptosis of lactotropes is mediated by the short isoform of D2  receptor","volume":"6","author":"Radl","year":"2011","journal-title":"PloS One"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00768","article-title":"The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas","volume":"9","author":"Liu","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11060-009-0107-y","article-title":"Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior","volume":"99","author":"Wu","year":"2010","journal-title":"J Neurooncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0933","article-title":"Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016","volume":"178","author":"McCormack","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-10-0629","article-title":"Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases","volume":"163","author":"Losa","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2924","article-title":"DNA ypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors","volume":"98","author":"Hirohata","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70728-8","article-title":"Temozolomide: a novel treatment for pituitary carcinoma","volume":"7","author":"Lim","year":"2006","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2983","article-title":"Temozolomide in the Era of Precision Medicine","volume":"77","author":"Thomas","year":"2017","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-19-0083","article-title":"How and when to use temozolomide to treat aggressive pituitary tumours","volume":"26","author":"Whitelaw","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0268","article-title":"PABPC1 relevant bioinformatic profiling and prognostic value in gliomas","volume":"16","author":"Wang","year":"2020","journal-title":"Future Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.616339\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T14:43:20Z","timestamp":1615560200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.616339\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":26,"alternative-id":["10.3389\/fendo.2021.616339"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.616339","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"article-number":"616339"}}